Fluoguide AS (FLUO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fluoguide AS (FLUO) has a cash flow conversion efficiency ratio of 4.485x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.97 Million ≈ $-1.18 Million USD) by net assets (Skr-2.44 Million ≈ $-263.12K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FLUO equity financing ratio to measure how much of total assets are equity-financed.
Fluoguide AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Fluoguide AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Fluoguide AS (FLUO) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Fluoguide AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fluoguide AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regis Corporation Common Stock
NYSE:RGS
|
0.009x |
|
Sreeleathers Limited
NSE:SREEL
|
0.037x |
|
Kedoya Adyaraya Tbk PT
JK:RSGK
|
-0.004x |
|
Inspirato Inc
NASDAQ:ISPO
|
0.016x |
|
Hil Industries Bhd
KLSE:8443
|
-0.027x |
|
Sleep Cycle AB
ST:SLEEP
|
0.150x |
|
Harmoney Corp Ltd
AU:HMY
|
0.514x |
|
StoneBridge Ventures Inc.
KQ:330730
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Fluoguide AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Fluoguide AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see FLUO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr23.07 Million ≈ $2.48 Million |
Skr-29.15 Million ≈ $-3.14 Million |
-1.264x | +49.46% |
| 2023-12-31 | Skr12.72 Million ≈ $1.37 Million |
Skr-31.81 Million ≈ $-3.42 Million |
-2.501x | -112.36% |
| 2022-12-31 | Skr31.97 Million ≈ $3.44 Million |
Skr-37.65 Million ≈ $-4.05 Million |
-1.178x | -202.57% |
| 2021-12-31 | Skr38.70 Million ≈ $4.16 Million |
Skr-15.06 Million ≈ $-1.62 Million |
-0.389x | +80.60% |
| 2020-12-31 | Skr4.41 Million ≈ $474.69K |
Skr-8.85 Million ≈ $-952.08K |
-2.006x | +13.68% |
| 2019-12-31 | Skr4.54 Million ≈ $488.79K |
Skr-10.55 Million ≈ $-1.14 Million |
-2.323x | -1390.74% |
| 2018-12-31 | Skr7.00K ≈ $753.31 |
Skr-1.09K ≈ $-117.41 |
-0.156x | -- |
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more